We show that blocking EGFR with cetuximab inhibits the activation of several pathways downstream of EGFR and results in an increased production of inflammatory chemokines and attraction of T cells when the tumor cells are stimulated with IFNγ and TNFα. The gene discussed is IFNG; the disease is neoplasm.